Table 4.
Studies assessing sarcopenia in patients undergoing TACE or TARE
| Author (year) | Region | Technique | N. patients | Outcome | Methods for sarcopenia assessment | N. of sarcopenic patients | Cut off |
|---|---|---|---|---|---|---|---|
| Kobayashi (2018) [53] | Asia | TACE | 102 | Overall survival |
L3 SMI ΔL3 SMI over 6 month |
31 41 |
M: < 42 cm2/m2 W: < 38 cm2/m2 ΔL3 SMI < -4.6 |
| Loosen (2019) [14] | Europe | TACE |
56 (HCC = 46, Metastases = 10) |
Treatment response Overall survival |
PMI Δ PMI |
< 11.8 mm/m2 < 13.39 mm/m2 |
|
| Fujita (2019) [54] | Asia | TACE | 179 | Overall survival |
PMI CPMI |
80 |
M: < 6 cm2/m2 W: < 3.4 cm2/m2 |
| Dodson (2019) [55] | America |
TACE DEB TACE TARE |
216 HCC = 109 Other = 107 |
Complication Overall survival |
TPA | 55 |
M: < 477 mm/m2 W: < 338 mm/m2 |
| Faron (2020) [56] | Europe | TARE | 58 |
Overall survival Progression free survival |
FFMA | 29 |
M < 3582 mm2 W < 2301 mm2 |
CPMI Changes in PMI per month during the TACE period, BED TACE drug-eluting bead TACE, FFMA derived fat-free muscle area, HCC hepatocellular carcinoma, PMI psoas muscle index, SMI skeletal muscle index, TACE trans-arterial chemoembolization, TARE trans-arterial radioembolization, TPA Total psoas area